Source: Eur Respir Rev, 29 (155) 190052; 10.1183/16000617.0052-2019
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Nicolas Guibert, Anne Pradines, Gilles Favre, Julien Mazieres. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev, 29 (155) 190052; 10.1183/16000617.0052-2019

Member's Comments

No comment yet.

Related content which might interest you: Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer Source: Eur Respir J, 54 (1) 1900649; 10.1183/13993003.00649-2019 Year: 2019 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Interdisciplinary multimodality management of stage III nonsmall cell lung cancer Source: Eur Respir Rev, 28 (152) 190024; 10.1183/16000617.0024-2019 Year: 2019 The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections Source: Eur Respir J, 56 (5) 2002595; 10.1183/13993003.02595-2020 Year: 2020 The comparison of clinical and pathological stages of the non-small cell lung carcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 89s Year: 2006 Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Comparison of clinic and pathological staging in non-small cell lung cancer Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017